Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
March 18, 2024 16:05 ET
|
Eyenovia, Inc.
Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery Reacquired development and commercialization rights to...
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
March 13, 2024 07:00 ET
|
Eyenovia, Inc.
EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion...
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
March 11, 2024 07:00 ET
|
Eyenovia, Inc.
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic pharmaceutical technology company, today announced that the Company will release financial...
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
March 05, 2024 08:00 ET
|
Eyenovia, Inc.
Approval based on nearly 9 out of 10 patients achieving complete absence of post-surgical pain and 6 out of 10 achieving total absence of inflammation within 15 days post-ocular surgery Eyenovia...
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
February 13, 2024 07:00 ET
|
Eyenovia, Inc.
Redwood City, California to complement Eyenovia’s facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi NEW YORK, Feb. ...
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada
January 16, 2024 07:00 ET
|
Eyenovia, Inc.
MicroPine, currently in late phase III for pediatric progressive myopia, to complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007 Part of corporate...
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023 16:05 ET
|
Eyenovia, Inc.
Acquired U.S. commercial rights to APP13007, currently under FDA review for post-surgical ocular pain and inflammation, from Formosa Pharmaceuticals Announced FDA approval of Coastline...
Eyenovia to Report Third Quarter 2023 Results on Monday, November 13
November 06, 2023 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for...
Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production
November 02, 2023 07:00 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for...
Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program
October 30, 2023 07:00 ET
|
Eyenovia, Inc.
Course to provide ophthalmic technicians with background on the Optejet dispensing technology and training on the use of Mydcombi™ for mydriasis NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) --...